Suzuki Indo Business

Most business people readily accept positive financial outcomes as business benefits. These are easy to measure in terms such as cost savings, revenue growth, cash inflows, or increased profits.

You are here: Home - Pfizers Revatio


Tag Archives: Pfizers Revatio

Antihypertensives Market To 2016

In 2009, the global anti-hypertensive market was estimated to be worth $27.2 billion, representing a Compound Annual Growth Rate (CAGR) of 5.0% between 2002 and 2009. The market is forecast to reach $30 billion by 2016, indicating a CAGR of 1.5% between 2009 and 2016. The primary reason for slight and gradual growth in the market is the patent expiries of major blockbusters, which are expected to decrease the annual cost of therapy after 2007.

For Sample Pages, please click or add the below link to your browser:
http://www.gbiresearch.com/RequestSamplePages.aspx?ID=Antihypertensives-Market-to-2016-Generic-Erosion-Following-Patent-Expiry-of-Major-ARBs-to-Impact-the-Market&Title=Pharmaceuticals_and_Healthcare&ReportType=Industry_Report

The global anti-hypertensive market is expected to witness a series of patent expiries between 2007 and 2015, which includes most of the top selling blockbuster drugs in the anti-hypertensive market. The major drugs that are set to lose patent protection include Novartiss Diovan (2012), Sanofi Aventiss Avapro (2012), Novartiss Exforge (2012), Takeda/AstraZenecas Blopress/Atacand (2012), Pfizers Revatio (2012), Actelions Tracleer (2015), and United Therapeutics Remodulin (2014). All these drugs together accounted for more than $19.4 billion in revenues in 2009. Mercks Cozaar patent expired in April 2010. The sales of Cozaar for the year 2009 were $3.6 billion. Pfizers Norvasc, which was once the worlds most prescribed drug for hypertension and angina, saw a sales decline of 12% in 2009 due to genericization in 2007. Thus, the series of upcoming patent expiries in the hypertension as well as PAH markets are set to lead to a decline in the market in the near future. However, due to increased usage of fixed dose-combinations and the entry of generics, the market is expected to rise slightly after 2015.

The current anti-hypertensive pipeline does offer some promising novel products, such as SPP635, Actos, LCZ696, QT1571, ACT-293987, PS-433540, Macitentan and Riociguat, indicated for the treatment of hypertension and PAH. However, the revenues generated from these products are not expected to completely make up for the revenue losses due to patent expiries. Thus, the overall global anti-hypertensive market is expected to show flat growth during the forecast period.

GBI Research, a leading business intelligence provider, has released its latest research Antihypertensives Market to 2016 – Generic Erosion Following Patent Expiry of Major ARBs to Impact the Market. The report provides in-depth analysis of the unmet needs, drivers and barriers that affect the global antihypertensive market. The report analyzes the markets for antihypertensive disorders in the US, the top five markets in Europe (the UK, Germany, France, Italy and Spain), and Japan. Treatment usage patterns, sales, prices and volumes are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Furthermore, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

For further details, please click or add the below link to your browser:
http://www.gbiresearch.com/Report.aspx?ID=Antihypertensives-Market-to-2016-Generic-Erosion-Following-Patent-Expiry-of-Major-ARBs-to-Impact-the-Market&ReportType=Industry_Report&Title=Pharmaceuticals_and_Healthcare

Visit our report store: http://www.gbiresearch.com

For more details contact:
[emailprotected]
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782